A
Andreas Kuhn
Researcher at University of Hohenheim
Publications - 154
Citations - 9353
Andreas Kuhn is an academic researcher from University of Hohenheim. The author has contributed to research in topics: Membrane protein & Transmembrane protein. The author has an hindex of 43, co-authored 133 publications receiving 7457 citations. Previous affiliations of Andreas Kuhn include Oklahoma State University Center for Health Sciences & University of Basel.
Papers
More filters
Journal ArticleDOI
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin,Evelyna Derhovanessian,Matthias Miller,Björn-Philipp Kloke,Petra Simon,Martin Löwer,Valesca Bukur,Arbel D. Tadmor,Ulrich Luxemburger,Barbara Schrörs,Tana Omokoko,Mathias Vormehr,Christian Albrecht,Anna Paruzynski,Andreas Kuhn,Janina Buck,Sandra Heesch,Katharina H Schreeb,Felicitas Müller,Inga Ortseifer,Isabel Vogler,Eva Godehardt,Sebastian Attig,Richard Rae,Andrea Breitkreuz,Claudia Tolliver,Martin Suchan,Goran Martic,Alexander Hohberger,Patrick Sorn,Jan Diekmann,Janko Ciesla,Olga Waksmann,Alexandra-Kemmer Brück,Meike Witt,Martina Zillgen,Andrée Rothermel,Barbara Kasemann,David Langer,Stefanie Bolte,Mustafa Diken,Sebastian Kreiter,Romina Nemecek,Christoffer Gebhardt,Christoffer Gebhardt,Stephan Grabbe,Christoph Höller,Jochen Utikal,Jochen Utikal,Christoph Huber,Carmen Loquai,Özlem Türeci +51 more
TL;DR: The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.
Journal ArticleDOI
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz,Mustafa Diken,Heinrich Haas,Sebastian Kreiter,Carmen Loquai,Kerstin C. Reuter,Martin Meng,Daniel Fritz,Fulvia Vascotto,Hossam Hefesha,Christian Grunwitz,Mathias Vormehr,Yves Hüsemann,Abderraouf Selmi,Andreas Kuhn,Janina Buck,Evelyna Derhovanessian,Richard Rae,Sebastian Attig,Jan Diekmann,Robert A. Jabulowsky,Sandra Heesch,Jessica C. Hassel,Peter Langguth,Stephan Grabbe,Christoph Huber,Özlem Türeci,Ugur Sahin +27 more
TL;DR: It is shown that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands.
Journal ArticleDOI
YidC mediates membrane protein insertion in bacteria.
James C. Samuelson,Minyong Chen,Fenglei Jiang,Ines Möller,Martin Wiedmann,Andreas Kuhn,Gregory J. Phillips,Ross E. Dalbey +7 more
TL;DR: It is shown that membrane insertion of two Sec-independent proteins requires YidC, which is essential for E. coli viability and homologues are present in mitochondria and chloroplasts.
Journal ArticleDOI
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin,Petra Oehm,Evelyna Derhovanessian,Robert A. Jabulowsky,Mathias Vormehr,Maike Gold,Daniel Maurus,Doreen Schwarck-Kokarakis,Andreas Kuhn,Tana Omokoko,Lena M. Kranz,Mustafa Diken,Sebastian Kreiter,Heinrich Haas,Sebastian Attig,Richard Rae,Katarina Cuk,Alexandra Kemmer-Brück,Andrea Breitkreuz,Claudia Tolliver,Janina Caspar,Juliane Quinkhardt,Lisa Hebich,Malte Stein,Alexander Hohberger,Isabel Vogler,Inga Liebig,Stephanie Renken,Julian Sikorski,Melanie Leierer,Verena Müller,Heidrun Mitzel-Rink,Matthias Miederer,Christoph Huber,Stephan Grabbe,Jochen Utikal,Andreas Pinter,Roland Kaufmann,Jessica C. Hassel,Carmen Loquai,Özlem Türeci +40 more
TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.
Journal ArticleDOI
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Annette B. Vogel,Isis Kanevsky,Ye Che,Kena A. Swanson,Alexander Muik,Mathias Vormehr,Lena M. Kranz,Kerstin C. Walzer,Stephanie Hein,Alptekin Güler,Jakob Loschko,Mohan S. Maddur,Ayuko Ota-Setlik,Tompkins Kristin Rachael,Journey Cole,Bonny Gaby Lui,Thomas Ziegenhals,Arianne Plaschke,David Eisel,Sarah C. Dany,Stephanie Fesser,Stephanie Erbar,Ferdia Bates,Diana Schneider,Bernadette Jesionek,Bianca Sänger,Ann Kathrin Wallisch,Yvonne Feuchter,Hanna Junginger,Stefanie A. Krumm,Andre P. Heinen,Petra Adams-Quack,Julia Schlereth,Stefan Schille,Christoph Kröner,Ramón de la Caridad Güimil Garcia,Thomas Hiller,Leyla Fischer,Rani S. Sellers,Shambhunath Choudhary,Olga Gonzalez,Fulvia Vascotto,Matthew R. Gutman,Jane Fontenot,Shannan Hall-Ursone,Kathleen M. Brasky,Matthew C. Griffor,Seungil Han,Andreas A.H. Su,Joshua A. Lees,Nicole L. Nedoma,Ellene H. Mashalidis,Parag Sahasrabudhe,Charles Tan,Danka Pavliakova,Guy Singh,Camila R. Fontes-Garfias,Michael W. Pride,Ingrid L. Scully,Tara Ciolino,Jennifer Obregon,Michal Gazi,Ricardo Carrion,Kendra J. Alfson,Warren Kalina,Deepak Kaushal,Pei Yong Shi,Thorsten Klamp,Corinna Rosenbaum,Andreas Kuhn,Özlem Türeci,Philip R. Dormitzer,Kathrin U. Jansen,Ugur Sahin +73 more
TL;DR: In this article, the authors report the preclinical development of two vaccine candidates (BNT162b1 and BNT 162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles.